{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T19:30:56Z","timestamp":1793129456911,"version":"4.5.0"},"reference-count":69,"publisher":"American Society for Clinical Investigation","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,2,22]]},"abstract":"<jats:p>\n                    EBV infection is associated with a number of malignancies of clinical unmet need, including Hodgkin lymphoma, nasopharyngeal carcinoma, gastric cancer, and posttransplant lymphoproliferative disease (PTLD), all of which express the EBV protein latent membrane protein 2A (LMP2A), an antigen that is difficult to target by conventional antibody approaches. To overcome this, we utilized phage display technology and a structure-guided selection strategy to generate human T cell receptor\u2013like (TCR-like) monoclonal antibodies with exquisite specificity for the LMP2A-derived nonamer peptide, C\n                    <jats:sub>426<\/jats:sub>\n                    LGGLLTMV\n                    <jats:sub>434<\/jats:sub>\n                    (CLG), as presented on HLA-A*02:01. Our lead construct, clone 38, closely mimics the native binding mode of a TCR, recognizing residues at position P3\u2013P8 of the CLG peptide. To enhance antitumor potency, we constructed dimeric T cell engaging bispecific antibodies (DiBsAb) of clone 38 and an affinity-matured version clone 38-2. Both DiBsAb showed potent antitumor properties in vitro and in immunodeficient mice implanted with EBV transformed B lymphoblastoid cell lines and human T cell effectors. Clone 38 DiBsAb showed a stronger safety profile compared with its affinity-matured variant, with no activity against EBV\n                    <jats:sup>\u2013<\/jats:sup>\n                    tumor cell lines and a panel of normal tissues, and was less cross-reactive against HLA-A*02:01 cells pulsed with a panel of CLG-like peptides predicted from a proteomic analysis. Clone 38 was also shown to recognize the CLG peptide on other HLA-A*02 suballeles, including HLA-A*02:02, HLA-A*02:04, and HLA-A*02:06, allowing for its potential use in additional populations. Clone 38 DiBsAb is a lead candidate to treat EBV malignancies with one of the strongest safety profiles documented for TCR-like mAbs.\n                  <\/jats:p>","DOI":"10.1172\/jci.insight.97805","type":"journal-article","created":{"date-parts":[[2018,2,21]],"date-time":"2018-02-21T11:00:58Z","timestamp":1519210858000},"source":"Crossref","is-referenced-by-count":49,"title":["TCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignancies"],"prefix":"10.1172","volume":"3","author":[{"given":"Mahiuddin","family":"Ahmed","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Lopez-Albaitero","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry","family":"Pankov","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian H.","family":"Santich","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Liu","sequence":"additional","affiliation":[{"name":"Eureka Therapeutics, Emeryville, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su","family":"Yan","sequence":"additional","affiliation":[{"name":"Eureka Therapeutics, Emeryville, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Xiang","sequence":"additional","affiliation":[{"name":"Eureka Therapeutics, Emeryville, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Wang","sequence":"additional","affiliation":[{"name":"Eureka Therapeutics, Emeryville, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisha N.","family":"Hasan","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamalai","family":"Selvakumar","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"O\u2019Reilly","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Liu","sequence":"additional","affiliation":[{"name":"Eureka Therapeutics, Emeryville, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6323-5171","authenticated-orcid":true,"given":"Nai-Kong V.","family":"Cheung","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"232","published-online":{"date-parts":[[2018,2,22]]},"reference":[{"issue":"11 Pt 2","key":"B1","first-page":"3","article-title":"Sero-epidemiology of the Epstein-Barr virus: preliminary analysis of an international study - a review","author":"de-The","year":"1975","journal-title":"IARC Sci Publ"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.25.022106.141553"},{"issue":"Pt 1","key":"B3","first-page":"151","article-title":"EBV Persistence--Introducing the Virus","volume":"390","author":"Thorley-Lawson","year":"2015","journal-title":"Curr Top Microbiol Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1186\/1750-9378-9-38"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-6655-4_19"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2012.111"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2013.96"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v11.i5.629"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0034276"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1049803"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0737"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-10265-6"},{"issue":"12","key":"B13","doi-asserted-by":"crossref","first-page":"7428","DOI":"10.1128\/jvi.67.12.7428-7435.1993","article-title":"HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2","volume":"67","author":"Lee","year":"1993","journal-title":"J Virol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-236356"},{"key":"B15","doi-asserted-by":"crossref","DOI":"10.1038\/srep03232","article-title":"Defining the expression hierarchy of latent T-cell epitopes in Epstein-Barr virus infection with TCR-like antibodies","volume":"3","author":"Sim","year":"2013","journal-title":"Sci Rep"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-707836"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/ni942"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/384134a0"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80546-4"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20042323"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2009.11.003"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003150"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0900556"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S0952-7915(01)00298-9"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1126\/science.1158545"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.125"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.4161\/2162402X.2014.989776"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1089\/152581602753658466"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1215"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2015.12.002"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3006034"},{"key":"B32","doi-asserted-by":"crossref","DOI":"10.1017\/erm.2012.2","article-title":"T-cell-receptor-like antibodies - generation, function and applications","volume":"14","author":"Dahan","year":"2012","journal-title":"Expert Rev Mol Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.132285699"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-299248"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2011.66"},{"issue":"176","key":"B36","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005661","article-title":"Targeting the intracellular WT1 oncogene product with a therapeutic human antibody","volume":"5","author":"Dao","year":"2013","journal-title":"Sci Transl Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.iy.07.040189.003125"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.23.021704.115658"},{"issue":"11","key":"B39","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.4049\/jimmunol.149.11.3580","article-title":"Sequence motifs important for peptide binding to the human MHC class I molecule, HLA-A2","volume":"149","author":"Parker","year":"1992","journal-title":"J Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/S0952-7915(01)00298-9"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80178-8"},{"issue":"1","key":"B42","doi-asserted-by":"crossref","first-page":"106","DOI":"10.4049\/jimmunol.162.1.106","article-title":"A single specific amino acid residue in peptide antigens is sufficient to activate memory CTL: potential role of cross-reactive peptides in memory T cell maintenance","volume":"162","author":"Reali","year":"1999","journal-title":"J Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.5.1820"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3301570"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0051397"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.6.3064"},{"issue":"20","key":"B47","first-page":"5835","article-title":"Direct detection and quantitation of a distinct T-cell epitope derived from tumor-specific epithelial cell-associated mucin using human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells","volume":"62","author":"Cohen","year":"2002","journal-title":"Cancer Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.8.4349"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200737524"},{"key":"B50","article-title":"Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor","volume":"4","author":"Zhang","year":"2014","journal-title":"Sci Rep"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-0928"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1301769"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0901425106"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1002376"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.8.5088"},{"key":"B56","article-title":"Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor","volume":"4","author":"Zhang","year":"2014","journal-title":"Sci Rep"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-540-46091-6_20"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2015.60"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2005.11.001"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1084\/jem.173.4.1007"},{"key":"B61","article-title":"MHC-peptide tetramers to visualize antigen-specific T cells","volume":"Chapter 17","author":"Altman","year":"2003","journal-title":"Curr Protoc Immunol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1271\/bbb.80640"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01457-14"},{"issue":"4","key":"B64","first-page":"276","article-title":"Establishment and characterization of an Epstein-Barr virus (EBC)-negative lymphoblastoid B cell line (BJA-B) from an exceptional, EBV-genome-negative African Burkitt\u2019s lymphoma","volume":"22","author":"Menezes","year":"1975","journal-title":"Biomedicine"},{"issue":"43","key":"B65","first-page":"210","article-title":"Artificial antigen presenting cells that express prevalent HLA alleles: A step towards the broad application of antigen-specific adoptive cell therapies","volume":"8","author":"Hasan","year":"2009","journal-title":"Discov Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.03.025"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0230-T"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.8.1.113"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1002\/art.30424"}],"container-title":["JCI Insight"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/insight.jci.org\/articles\/view\/97805\/files\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T13:04:13Z","timestamp":1779195853000},"score":1,"resource":{"primary":{"URL":"https:\/\/insight.jci.org\/articles\/view\/97805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,22]]},"references-count":69,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,2,22]]},"published-print":{"date-parts":[[2018,2,22]]}},"alternative-id":["10.1172\/jci.insight.97805"],"URL":"https:\/\/doi.org\/10.1172\/jci.insight.97805","relation":{},"ISSN":["2379-3708"],"issn-type":[{"value":"2379-3708","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,22]]},"article-number":"e97805"}}